Patent intelligence · US
US 12364764
Sustained release thermosetting gels comprising sodium channel blockers and the methods of making same
Sustained release thermosetting gels comprising sodium channel blockers and the methods of making same
Patent details — US 12364764
- Jurisdiction
- US
- Status
- granted
- Grant date
- Jul 22, 2025
- Expiration
- Jul 17, 2045
- Applicant
- Pacira Therapeutics, Inc.
- Claims
- 24
- CPC classes
- A61K, A61K31/407, A61K47/34, A61K9/0019
Quick answer
US 12364764 (Sustained release thermosetting gels comprising sodium channel blockers and the methods of making same) is held by Pacira Therapeutics, Inc.. Status: granted. Granted Jul 22, 2025. Expires Jul 17, 2045 (19 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- Pacira Therapeutics, Inc.
- Grant date
- Expiration
- Claims
- 24
- CPC classes
- A61K, A61K31/407, A61K47/34, A61K9/0019, A61K9/0024, A61P
More from Pacira Therapeutics, Inc.
Related pharmaceutical patents in our USPTO index.
-
US 12370142
Manufacturing of bupivacaine multivesicular liposomes
granted -
US 12318483
Manufacturing of bupivacaine multivesicular liposomes
granted -
US 12296047
Manufacturing of bupivacaine multivesicular liposomes
granted -
US 12285435
Multivesicular liposome formulations of dexamethasone
granted -
US 12285419
Bupivacaine multivesicular liposome formulations and uses thereof
granted -
US 12280149
Manufacturing of bupivacaine multivesicular liposomes
granted -
US 12251472
Manufacturing of bupivacaine multivesicular liposomes
granted
Frequently asked questions
What is US patent 12364764?
US 12364764 (Sustained release thermosetting gels comprising sodium channel blockers and the methods of making same) is held by Pacira Therapeutics, Inc.. Status: granted. Granted Jul 22, 2025. Expires Jul 17, 2045 (19 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 12364764?
Pacira Therapeutics, Inc. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 57 pharmaceutical patents for this assignee.
When does US 12364764 expire?
Our index shows an expiration date of Jul 17, 2045 (19 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.